Evidence map›Paper›PMID 25100609›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2014

Low-intensity repetitive transcranial magnetic stimulation improves abnormal visual cortical circuit topography and upregulates BDNF in mice.

Kalina Makowiecki, Alan R Harvey, Rachel M Sherrard, Jennifer Rodger

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.

  1. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2021
    Guideline
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Mechanisms of Action of TMS in the Treatment of Depression.Current topics in behavioral neurosciences · 2024
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Kalina MakowieckiExperimental and Regenerative Neuroscience, School of Animal Biology, and.
Alan R HarveyExperimental and Regenerative Neuroscience, School of Animal Biology, and School of Anatomy, Physiology and Human Biology, The University of Western Australia, Crawley, Western Australia 6009, and.
Rachel M SherrardSorbonne Universités, Pierre and Marie Curie University of Paris 06 and Centre National de la Recherche Scientifique, Institut de Biologie Paris Seine, UMR8256 Biological Adaptation and Ageing, F-75005 Paris, France.
Jennifer RodgerExperimental and Regenerative Neuroscience, School of Animal Biology, and jennifer.rodger@uwa.edu.au.
Center for Neuroscience and Regenerative Medicine · USInstitut de Biologie Paris-Seine · FRUniversity of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Repetitive transcranial magnetic stimulation (rTMS) is increasingly used as a treatment for neurological and psychiatric disorders. Although the induced field is focused on a target region during rTMS, adjacent areas also receive stimulation at a lower intensity and the contribution of this perifocal stimulation to network-wide effects is poorly defined. Here, we examined low-intensity rTMS (LI-rTMS)-induced changes on a model neural network using the visual systems of normal (C57Bl/6J wild-type, n = 22) and ephrin-A2A5(-/-) (n = 22) mice, the latter possessing visuotopic anomalies. Mice were treated with LI-rTMS or sham (handling control) daily for 14 d, then fluorojade and fluororuby were injected into visual cortex. The distribution of dorsal LGN (dLGN) neurons and corticotectal terminal zones (TZs) was mapped and disorder defined by comparing their actual location with that predicted by injection sites. In the afferent geniculocortical projection, LI-rTMS decreased the abnormally high dispersion of retrogradely labeled neurons in the dLGN of ephrin-A2A5(-/-) mice, indicating geniculocortical map refinement. In the corticotectal efferents, LI-rTMS improved topography of the most abnormal TZs in ephrin-A2A5(-/-) mice without altering topographically normal TZs. To investigate a possible molecular mechanism for LI-rTMS-induced structural plasticity, we measured brain derived neurotrophic factor (BDNF) in the visual cortex and superior colliculus after single and multiple stimulations. BDNF was upregulated after a single stimulation for all groups, but only sustained in the superior colliculus of ephrin-A2A5(-/-) mice. Our results show that LI-rTMS upregulates BDNF, promoting a plastic environment conducive to beneficial reorganization of abnormal cortical circuits, information that has important implications for clinical rTMS.

Indexed as

Brain DiseasesTranscranial Magnetic StimulationAnalysis of VarianceAnimalsBiophysicsBrain-Derived Neurotrophic FactorBrain MappingEphrin-A2Ephrin-A5Geniculate BodiesMiceMice, Inbred C57BLMice, TransgenicNeural PathwaysRNA, MessengerUp-RegulationBrain-Derived Neurotrophic FactorEphrin-A2Ephrin-A5RNA, Messengercorticotectal projectioncritical periodephrin-A2A5−/− micegeniculocorticalLI-rTMSplasticity

Identifiers

PMID25100609
PMCPMC4122806
OpenAlexW2138956975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.